On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…
CertaraFebruary 26, 2026
Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies
– London, UK
CertaraFebruary 24, 2026
Start right, finish strong: Antibody-drug conjugate (ADC) studies for success
Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…
CertaraFebruary 23, 2026
FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development
Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…
CertaraFebruary 18, 2026
Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)
Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…
CertaraFebruary 13, 2026
Pediatric Drug Development: From “Wild West” to Model-Informed Confidence
Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…
CertaraFebruary 11, 2026
Why Many Global Drugs Never Reach Japan
Despite faster reviews, many global drugs never reach Japan. Learn how early development decisions, trial…
CertaraFebruary 5, 2026
